SUMMARY A solid-phase separation fluoroimmunoassay for primidone in plasma or serum was developed using antibodies coupled to magnetisable cellulose/iron oxide particles and a fiuoresceinlabelled primidone derivative as tracer. Endogenous fiuorophores and other potentially interfering components in serum samples were reliably and completely removed at the time the antibody-bound and free fractions were being separated. The separation and wash steps were greatly facilitated by use of magnetic sedimentation. The assay reached equilibrium within 30 minutes; all normal reliability criteria were satisfied; and the results correlated closely with those of an established enzymoimmunoassay method. The assay is specific for primidone, and no detectable interference by all other commonly employed anticonvulsants was found at serum levels of 1 gil.
Primidone (5-phenyl-5-ethylhexahydropyrimidine-4, 6-dione) has been widely used as an anticonvulsant drug since its introduction in the early 1950s. There is evidence from animal work and human studies that primidone and its two major metabolites, phenylethylmalonamide (PEMA) and phenobarbital, all have anticonvulsant activity.lr" Routine monitoring of serum levels of primidone is required to assess patient compliance and to differentiate toxic effects from those due to the underlying disease. The half-life of primidone is short, and therefore serum levels fluctuate widely between doses, the ratio of primidone to derived phenobarbital showing considerable inter-individual variability. The metabolism of primidone is affected by other anticonvulsants, the clearance being approximately halved by the concomitant administration of phenytoin, carbamazepine, and phenobarbital." Conversely, its metabolism is impaired by isoniazid and possibly by sodium aminosalicylate" with an approximate doubling of the clearance time and marked rise in circulating levels.
At the present time several methods are available for the quantitative measurement of primidone levels in serum, plasma, or saliva. Despite recent developments with high-pressure liquid chromatography" and gas-liquid chromatography," immunoassays are most widely used" because they are technically simple and permit direct analysis of small sample volumes with a high throughput.
We describe a fluoroimmunoassay (FIA) for primidone which employs antiserum covalently coupled to magnetisable solid-phase particles" and fluorescein-labelled drug as tracer.
Methods
Primidone was obtained from ICI (Macclesfield, Cheshire, UK); phenobarbital, fluorescein isothiocyanate isomer I (FITC), barbituric acid, glutethimide, hexobarbital, and bovine albumin (type A 4503) from Sigma (Poole, Dorset, UK); p-hydroxyphenobarbital from Aldrich (Gillingham, Dorset, UK); silica gel thin-layer chromatography sheets (DC-Alufolien Kieselgel 60 F 254, Art. 5554) from E Merck (Darmstadt, FRG); and pooled normal human serum from ILS (London, UK). Other drugs employed in the specificity studies were gifts from their respective UK distributors.
PREPARATION OF 4-AMINOPHENYL PRIMIDONE (Fig. 1, II To a solution of 46 mg 4-aminophenyl primidone (II) in hydrochloric acid (2 ml, 100 mmol) at O°C was added solid sodium nitrite (20 mg). After stirring for 10 minutes, excess of nitrous acid was destroyed by the addition of urea (20 mg). The pH of the solution was adjusted to 8-9 with sodium bicarbonate (l molfl) solution. The diazotised amino-primidone solution was then added dropwise to a stirred solution of 2 ml bovine albumin (30 g/I) at O°C.
After 30 minutes the solution was dialysed against three 1-1 portions of distilled water for three days. The retentate on lyophilisation yielded 52 mg immunogen (IV) with a hapten/carrier ratio of 12:1 as estimated by IR difference spectroscopy against amino primidone/bovine albumin mixture.
ANTI-PRIMIDONE SERA
Three mature female Border-Leicester cross sheep were immunised following a previously described protocol.P Antiserum from the second bleed of one animal was used in the studies described in detail below.
ANTI-PRIMIDONE MAGNETISABLE SOLID-PHASE
This was prepared following established procedures," Zinc chloride (500 g) was dissolved in distilled water, and cellulose (50 g) was added, followed by iron oxide (50 g). The mixture was stirred for 1 hour during which the viscosity increased noticeably. The mixture was dispensed by a syringe into HCI (200 mmol/l). The resulting hard gel was washed with water for 1 hour and dried in a hot-air oven at 80 DC for 48 hours. The product was ground to a size of approximately BOO fLm, again washed with water, and stirred in 1-1 ethylenediamine tetracetic acid disodium salt (200 mmolfl) overnight to remove the remaining zinc chloride. The particles were washed repeatedly with water, dried in the oven, and then milled in a ball mill to a size of I to 10 fLm with a peak between 2 and 4 urn. The particles were discharged through a steel mesh box into a beaker where they were sedimented on a magnetic block. The supernatant was aspirated and the particles were washed six times with distilled water.
One gram of the cellulose/iron oxide particles was riashed twice with 20--30ml sodium phosphate buffer (50 rnrnol/l, pH II· 5) and suspended in 10 ml of the same buffer. The particles were activated by the addition of cyanogen bromide solution (l gin 15 ml Df the sodium phosphate buffer). The mixture was stirred for 12 minutes, during which time the pH was kept between 11·3 and 11·7 by addition of 2 rnol/l sodium hydroxide. The activated magnetisable particles were washed four times with 20--30ml ice-cold distilled water, followed by two washes with 20-30 ml ice-cold sodium bicarbonate buffer (lOOrnmol/l, pH 8·6). Finally, the activated particles were suspended in 10 ml bicarbonate buffer to which 2 ml of the whole antiserum was added, and the solution was mixed for 24 hours. The uncoupled antibody was removed by washing the solid phase twice with 20--30 ml of the sodium bicarbonate buffer. All remaining reactive sites were blocked by suspending the antibody-coupled particles for 1 hour in 20 ml of the sodium bicarbonate buffer containing 50 mmol/I ethanolamine. After sedimenting the particles, the supernatant was removed and the particles were suspended in sodium acetate buffer (100 mrnol/l, pH 4·0) for 30 minutes and then resuspended in fresh acetate buffer for 3 hours. Finally, the particles were washed three times with the assay diluent buffer, suspended in 20 ml of the same buffer, and stored at 4DC ready for use.
ASSAY STANDARDS
Primidone dissolved in methanol was added to pooled normal human serum, and the standards were stored at 4DC. Fluorometry: Fluorescence was measured directly in the disposable test tubes using either:
(a) Perkin-Elmer 1000 filter fluorometer modified as described previously," or (b) Wilj Fluoroflex fitted with fluorescein filters and test tube sample holder.
Assay protocol: Assays were performed at room temperature in duplicate. To 5 fLl assay standard or serum or plasma sample was added 100 fLl fluorescein-labelled primidone (574 nrnol/l) followed by 100 fLl anti-prirnidone solid phase (10 gil). After incubation for 30 minutes with constant mixing, 1 ml diluent buffer was added, the particles were sedimented by placing the rack containing the assay tubes on the magnet for 2-5 minutes, and the supernatants were aspirated to waste. Elution reagent (1· 4 ml) was then added, the tubes were vortexed, and the particles Precision: Three pools of selected patients' sera were each assayed 10 times in one assay, giving mean results of 3· 5, 10, and 30 mg/l with within-assay coefficients of variation of 6·5, 5·5, and 3·1 %, respectively. Assay of the same specimen on 10 different days gave between-assay coefficients of variation of 8·5,6·5, and 3·2 %,respectively.
Sensitivity:
The mean and standard deviation of the assay response at zero dose, found from the results of 20 replicates, were used to determine sensitivity according to the method of Rodbard.l! assuming that both standards and samples were determined in duplicate. The minimal detectable concentration of primidone at 95 %confidence level was 0·2 rngjl and the minimal detectable dose was 1 ng/tube.
Accuracy: Primidone was added at concentrations of 3·5, 10, and 30 mg/l to pooled normal human serum, and analytical recovery was 94·3, 99·5, and 98·3 %, respectively. Corresponding recoveries for prirnidone added to pooled normal human plasma were 95·7, 99·0, and 98·3 %, respectively.
Linearity: Three clinical samples containing high primidone concentrations were diluted 2, 5, and lO-foid with buffer, serum, or plasma and assayed in triplicate. The recoveries were calculated, and the results were 99, 98, and 97 % using buffer, serum, or plasma as the diluent successively. Non-specific binding was less than 2 %as determined using magnetisable particles covalently linked to non-immunised sheep serum (Fig. 2) .
Results
Ol~=t:::~==::f::=::::t=:;j In preliminary experiments it was necessary to find an eluting reagent which both eluted the tracer from the solid phase and also enhanced fluorescence. A mixture of methanol/sodium bicarbonate buffer (80/20, v/v) was suitable and proved easy to pipette or dispense with a repeating dispenser.
were again sedimented on the magnet. Finally, the fluorescence of the supernatants (containing the eluted bound fraction) was determined and a standard curve constructed by plotting the percentage of total fluorescence bound against serum standard concentration. valproate, glutethimide, and methoin did not crossreact in the FIA (no detectable interference at serum levels of 1 g/\). Cyclobarbital, heptobarbital, hexobarbital, pentobarbital, mephobarbital, barbital, p-hydroxyphenobarbital, and barbituric acid also showed no interference at levels of 1 gil.
CORRELATION WITH ESTABLISHED ASSA Y METHOD
Results of the assay of 50 patients' specimens by PIA (y) and by enzymoimmunoassay (x) were related by the regression line y = 1· 05x~0·9 (Fig. 4) , which was calculated on the assumption that the two methods have equal precision characteristics.P The correlation coefficient (r) was 0·99.
INTERFERENCES
Experiments performed in the absence of fluoresceinlabelled primidone showed no significant fluorescence after addition of the elution reagent. This confirms that endogenous fluorophores in serum or plasma are efficiently removed in the wash step. The possible effects of interfering factors were also assessed by adding to clinical samples of known protein, lipid, haemoglobin, and bilirubin content known amounts of primidone and assaying the samples in triplicate. Abnormal concentrations of total protein (up to 100 g/\), or lipid (up to 11·4 mmol/l triglyceride and 5·7 mrnol/l cholesterol), or haemoglobin (5 to 13 gil) or severely icteric samples with bilirubin concentrations up to 500 fLmol/1 did not interfere with the assay.
STABILITY OF REAGENTS
There was no change in the properties of the fluorescein-labelled primidone stored in methanol at 20°C over a one-year period. The primidone serum standards and the anti-primidone solid-phase were also stable for one year when stored at 4°C.
Discussion
Phenobarbital and PEMA are the main metabolites of primidone, and both contribute to the therapeutic effect. Because of the structural resemblance of these metabolites to the parent drug, a very specific assay is required for primidone if it is not wished to detect the metabolites.
Primidone was derivatised at its phenyl group for linkage to the carrier protein and fluorescein label. The specificity characteristics of the PIA shows that, as expected, there is optimum selectivity for the maximally exposed hexahydropyrimidine-4, 6-dione ring which must be intact if significant antibody binding is to occur. Thus the presence of a keto function, as in phenobarbital, abolishes binding. The primidone PIA is highly specific without any interference from any commonly used anticonvulsant drugs or barbiturates. In order to measure phenobarbital levels in samples containing primidone, a specific antiserum for phenobarbital is required." Recently, we have developed an FIA to measure both drugs simuitaneoulsy using two different fluorescent labels and a mixture of specific antisera for both drugs.l?
As compared with the determination of enzyme activity, the measurement of fluorescence is rapid and simple. In PIA studies in this laboratory, fluorescence readings are routinely taken in five seconds, using the signal-averaging facility of the Perkin-Elmer instrument. As previously demonstrated.l" fluorescence of the supernatants above sedimented solid phase may conveniently be determined directly in disposable polystyrene assay tubes. In the FIA the use of the separation step enabled the reliable and complete removal of serum fluorophores and other potentially interfering components.P The primidone FIA employs stable, non-radioactive reagents and may be performed using a simple filter fluorimeter. It requires a small sample volume (5 fLl) which should be beneficial in children, and the assay should be easily adaptable to measure salivary primidone levels. Sample throughput capacity is high, and no special sample preparation is required. Within-and between-assay precision and analytical recovery are satisfactory.
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